Development of an LC-MS/MS Method for ARV-110, a PROTAC Molecule, and Applications to Pharmacokinetic Studies

Development of an LC-MS/MS Method for ARV-110, a PROTAC Molecule, and Applications to Pharmacokinetic Studies

ARV-110, a novel proteolysis-targeting chimera (PROTAC), has been reported to show satisfactory safety and tolerability for prostate cancer therapy in phase I clinical trials. However, there is a lack of bioanalytical assays for ARV-110 determination in biological samples. In this study, we develope...

Full description

Bibliographic Details
Main Authors: Thi-Thao-Linh Nguyen, Jin Woo Kim, Hae-In Choi, Han-Joo Maeng, Tae-Sung Koo
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Molecules
Subjects:
ARV-110
proteolysis-targeting chimera
LC-MS/MS
validation
stability
pharmacokinetics
Online Access:https://www.mdpi.com/1420-3049/27/6/1977

Internet

https://www.mdpi.com/1420-3049/27/6/1977

Similar Items